Iwase H

No ORCID on file · 4 papers in corpus · active 2001-2022

Study types

  • article 2

Condition tags

  • endometriosis 2
2022
Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy.
Gynecology and Minimally Invasive Therapy ·doi:10.4103/gmit.gmit_9_22

For preparing the optimal condition in transcervical resection (TCR) surgery, gonadotropin-releasing hormone (GnRH) agonist has been utilized. Recently, an oral GnRH antagonist (relugolix) is available and acts directly on GnRH receptor, av…

article 2020
Relaxin-2 May Suppress Endometriosis by Reducing Fibrosis, Scar Formation, and Inflammation
Biomedicines ·doi:10.3390/biomedicines8110467

Background: Relaxin (RLX)-2, produced by the corpus luteum and placenta, is known to be potentially effective in fibrotic diseases of the heart, lungs, kidneys, and bladder; however, its effectiveness in endometriosis has not yet been inves…

2016
A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Breast cancer (Tokyo, Japan) ·doi:10.1007/s12282-015-0593-z

BackgroundLuteinizing hormone-releasing hormone (LH-RH) agonists provide effective adjuvant treatment for premenopausal women with endocrine-responsive breast cancer. Here, we investigated appropriate treatment durations of an LH-RH agonist…

article 2001
[Prevalence of endometriosis in ovarian cancer].
Nihon rinsho. Japanese journal of clinical medicine